Bio-Rad acquires AbD Serotec
Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products, has announced that it has purchased AbD Serotec, a division of MorphoSys, for approximately €53 million in cash.
AbD Serotec is one of the world’s leading antibody manufacturers, offering over 15,000 antibodies, kits and accessories. AbD Serotec has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as other facilities in Germany and the US.
“We are pleased to have AbD Serotec join Bio-Rad,” said Norman Schwartz, Bio-Rad President and CEO.
“With AbD Serotec’s comprehensive catalogue of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA and cell sorting.”
Director of scientific R&D firm fined $195K+ over biogas experiments
The fine follows a 2022 incident in which a doctor sustained serious injuries after exposure to...
7th edition of STEM Equity Monitor now available
The latest national data resource on diversity in STEM has new design features intended to...
Professor Girish Dwivedi wins 2026 WA Pearcey Entrepreneur of the Year Award
As part of the 35th annual WAITTA INCITE Awards, Dwivedi was recognised for his contribution to...
